BIOMARKER ANALYSES AND OVERALL SURVIVAL (OS) FROM THE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3, FASTACT-2 STUDY OF INTERCALATED ERLOTINIB WITH FIRST-LINE CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
Other conference paper


Full Text

Times Cited
Web of Science3WOS source URL (as at 21/01/2021) Click here for the latest count

Other information
All Author(s) ListMok TSK, Lee JS, Zhang L, Yu C, Thongprasert S, Ladrera GEI, Srimuninnimit V, Truman MI, Klughammer B, Wu Y
Name of Conference37th Congress of the European-Society-of-Medical-Oncology (ESMO)
Start Date of Conference28/09/2012
End Date of Conference02/10/2012
Place of ConferenceVienna
Country/Region of ConferenceAustria
Journal nameAnnals of Oncology
Detailed descriptionorganized by European Society for Medical Oncology,
Year2012
Month9
Day1
Volume Number23
PublisherOxford University Press (OUP): Policy B - Oxford Open Option B - CC-BY
Pages400 - 401
ISSN0923-7534
eISSN1569-8041
LanguagesEnglish-United Kingdom
Web of Science Subject CategoriesOncology; ONCOLOGY

Last updated on 2021-22-01 at 00:10